Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature

Department of Neurology, Osp. S. Andrea, Via Vittorio Veneto 197, 19100 La Spezia, Italy.
Journal of neurology, neurosurgery, and psychiatry (Impact Factor: 5.58). 03/2011; 82(3):306-8. DOI: 10.1136/jnnp.2009.188912
Source: PubMed

ABSTRACT A few case reports have shown controversial results of rituximab efficacy in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
To analyse the efficacy of rituximab in a large CIDP cohort.
A retrospective, observational and multicentre study on the use of rituximab in CIDP. 13 Italian CIDP patients were treated with rituximab after the partial or complete lack of efficacy of conventional therapies. Eight patients had co-occurring haematological diseases. Patients who improved by at least two points in standard clinical scales, or who reduced or discontinued the pre-rituximab therapies, were considered as responders.
Nine patients (seven with haematological diseases) responded to rituximab: six of them, who were non-responders to conventional therapies, improved clinically, and the other three maintained the improvement that they usually achieved with intravenous immunoglobulin or plasma exchange. Significantly associated with shorter disease duration, rituximab responses started after a median period of 2.0 months (range, 1-6) and lasted for a median period of 1 year (range, 1-5).
Rituximab seems to be a promising therapeutic choice when it targets both CIDP and co-occurring haematological diseases. Timely post-onset administration of rituximab seems to be associated with better responses.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Prolonged intravenous immunoglobulin (IVIG) therapy is used for the chronic autoimmune neuropathies CIDP and MMN, but the doses and treatment intervals are usually chosen empirically due to a paucity of data from dose-response studies. Recent studies of the electrophysiology and immunology of these diseases suggest that antibody-induced reversible dysfunction of nodes of Ranvier may play a role in conduction block and disability which responds to immunotherapy more rapidly than would be expected for demyelination or axonal damage per se. Clinical reports suggest that in some cases, the effects of each dose of IVIG may be transient, wearing-off before the next dose is due. These observations lead us to hypothesize that that therapeutic IgG acts by competing with pathologic autoantibodies and that individual patients may require different IgG levels for optimal therapeutic effects. Frequent IVIG dosing and weekly subcutaneous IgG have been tried as ways of continuously maintaining high serum IgG levels, resulting in stabilization of neuromuscular function in small case series. Frequent grip strength and disability measurements, performed by the patient at home and reported electronically, can be used to assess the extent and duration of responses to IgG doses. Individualization of IgG treatment regimens may optimize efficacy, minimize disability, and identify non-responders. This article is protected by copyright. All rights reserved. © 2014 Wiley Periodicals, Inc.
    Muscle & Nerve 11/2014; 51(3). DOI:10.1002/mus.24526 · 2.31 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Autoimmune neuropathies occur when immunologic tolerance to myelin or axonal antigens is lost. Even though the triggering factors and the underling immunopathology have not been fully elucidated in all neuropathy subsets, immunological studies on the patients' nerves, transfer experiments with the patients' serum or intraneural injections, and molecular fingerprinting on circulating autoantibodies or autoreactive T cells, indicate that cellular and humoral factors, either independently or in concert with each other, play a fundamental role in their cause. The review is focused on the main subtypes of autoimmune neuropathies, mainly the Guillain-Barré syndrome(s), the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), the Multifocal Motor Neuropathy (MMN), and the IgM anti-MAG-antibody mediated neuropathy. It addresses the factors associated with breaking tolerance, examines the T cell activation process including co-stimulatory molecules and key cytokines, and discusses the role of antibodies against peripheral nerve glycolipids or glycoproteins. Special attention is given to the newly identified proteins in the nodal, paranodal and juxtaparanodal regions as potential antigenic targets that could best explain conduction failure and rapid recovery. New biological agents against T cells, cytokines, B cells, transmigration and transduction molecules involved in their immunopathologic network, are discussed as future therapeutic options in difficult cases. This article is part of a Special Issue entitled: Neuromuscular Diseases: Pathology and Molecular Pathogenesis.
    Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 06/2014; 1852(4). DOI:10.1016/j.bbadis.2014.06.013 · 5.09 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: La polyradiculoneuropathie inflammatoire démyélinisante chronique (PIDC) est une maladie rare, mais la plus fréquente des polyneuropathies dysimmunitaires chroniques. Les enjeux thérapeutiques exigent en premier lieu d’améliorer les critères du diagnostic, qui reste difficile, en particulier dans les formes atypiques. Le second enjeu est d’établir des recommandations pour le traitement de première intention, dans la mesure où les corticoïdes, les immunoglobulines intraveineuses à fortes doses (IgIV) et les échanges plasmatiques (EP) ont démontré leur efficacité dans des essais randomisés controlés. Des publications récentes ont rapporté des résultats originaux dans l’utlisation de différentes voies d’administration des corticoïdes, et également dans l’étude des délais de rechute après un traitement de première intention conduit soit avec les corticoïdes, soit avec les IgIV. Ces résultats pourraient modifier la décision thérapeutique en première intention dans les PIDC en pratique quotidienne. Le troisième enjeu, aujourd’hui le plus complexe, concerne le traitement à long-terme des PIDC, dans la mesure où aucun traitement immunomodulateur n’a démontré son efficacité. Enfin, le dernier enjeu est celui des outils d’évaluation dans les essais randomisés controlés, mais aussi en pratique clinique. L’objectif de cette revue est de faire le point sur les derniers résultats publiés dans le diagnostic, le traitement et l’évaluation des PIDC, et de donner un aperçu de la prise en charge actuelle et future des PIDC.
    Revue Neurologique 10/2014; DOI:10.1016/j.neurol.2014.06.002 · 0.60 Impact Factor